Mounjaro Approved to Reduce Heart Event Risk in Type 2 Diabetes Patients
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in adults with type 2 diabetes and high cardiovascular risk.
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in adults with type 2 diabetes and high cardiovascular risk.
